Publications
| Title | Abstract | Year(sorted ascending) Filter | PMID Filter |
|---|
| bronchiolitis and pneumonia requiring hospitalization in young first nations children in northern ontario, canada. | high rates of lower respiratory tract infection (lrti), including bronchiolitis and pneumonia, have been reported in inuit infants living in arctic canada. we examined rates of lrti in first nations canadian infants living in the sioux lookout zone, in northern ontario. | 2014 | 24751861 |
| [expression of heparanase in kidney of rats with respiratory syncytial virus nephropathy and its relationship with proteinurina]. | to explore the role of heparanase in the pathogenesis of respiratory syncytial virus (rsv) nephropathy in rats model. | 2014 | 24749342 |
| mucosal delivery of a double-stapled rsv peptide prevents nasopulmonary infection. | respiratory syncytial virus (rsv) infection accounts for approximately 64 million cases of respiratory disease and 200,000 deaths worldwide each year, yet no broadly effective prophylactic or treatment regimen is available. rsv deploys paired, self-associating, heptad repeat domains of its fusion protein, rsv-f, to form a fusogenic 6-helix bundle that enables the virus to penetrate the host cell membrane. here, we developed hydrocarbon double-stapled rsv fusion peptides that exhibit stabilized α ... | 2014 | 24743147 |
| repurposing staples for viruses: applying peptide design to rsv prophylaxis. | respiratory syncytial virus (rsv) is responsible for lower respiratory tract infections and annually results in 200,000 deaths worldwide. despite the burden of rsv-associated disease, treatments and preventative measures are limited. in this issue of jci, bird and colleagues describe their work using a peptide stapling technique that allowed synthesis of a stable peptide mimic of a portion of the rsv fusion protein. pretreatment of cells with the stable peptide effectively blocked virus entry. w ... | 2014 | 24743141 |
| alternative mechanisms for respiratory syncytial virus (rsv) infection and persistence: could rsv be transmitted through the placenta and persist into developing fetal lungs? | respiratory syncytial virus (rsv) represents the most common respiratory pathogen observed worldwide in infants and young children and may play a role in the inception of recurrent wheezing and asthma in childhood. we discuss herein the recent hypothesis that rsv vertically transmitted from the mother to the fetus in utero causes persistent structural and functional changes in the developing lungs of the offspring, thereby predisposing to postnatal airway obstruction. | 2014 | 24810284 |
| development of an efficient qrt-pcr assay for quality control and cellular quantification of respiratory samples. | sample quality is a fundamental parameter for the successful diagnosis of respiratory viruses. this parameter depends upon the concentration of epithelial cells. respiratory samples are usually heterogeneous, which makes relative quantification of the viral load, against the quantity of cells, the most suitable measurement. the quantification of viral load in the field of respiratory viruses is a vital piece of information. quantification is required from rna or dna viral genomes extracted. | 2014 | 24809729 |
| clinical severity of rhinovirus/enterovirus compared to other respiratory viruses in children. | human rhinovirus/enterovirus (hrv/ent) infections are commonly identified in children with acute respiratory infections (aris), but data on their clinical severity remain limited. | 2014 | 24801963 |
| respiratory syncytial virus prophylaxis in down syndrome: a prospective cohort study. | children with down syndrome (ds) are at significant risk for respiratory syncytial virus (rsv) infection and related hospitalization. we compared hospitalization rates due to respiratory tract infection in children with ds aged <2 years who prospectively received palivizumab during the rsv season with a previously published, similar untreated ds birth cohort. | 2014 | 24799541 |
| frequency of apnea and respiratory viruses in infants with bronchiolitis. | the frequency of apnea in infants <12 months of age admitted with acute bronchiolitis was 5.16% (95% confidence interval: 3.94-6.72). most commonly detected viruses in the 51 apneic infants were respiratory syncytial virus (33.3%), rhinovirus (13.7%) and viral coinfections (23.5%). young age and prematurity were the main risk factors for apnea independent of the respiratory syncytial virus status. non-respiratory syncytial virus infants had a higher rate of prematurity. | 2014 | 24797994 |
| inhibition of stat6 during vaccination with formalin-inactivated rsv prevents induction of th2-cell-biased airway disease. | the pattern of immune response to a vaccine antigen can influence both efficacy and adverse events. th2-cell-deviated responses have been implicated in both human and murine susceptibility to enhanced disease following formalin-inactivated (fi) vaccines for measles and rsv. in this study, we used the th2-cell-deviated murine model of fi-rsv vaccination to test the ability of a dominant negative, cell-penetrating peptide inhibitor of stat6 (stat6 inhibitory peptide (ip)) to modulate the vaccine-i ... | 2014 | 24796717 |
| a new transcriptional role for matrix metalloproteinase-12 in antiviral immunity. | interferon-α (ifn-α) is essential for antiviral immunity, but in the absence of matrix metalloproteinase-12 (mmp-12) or iκbα (encoded by nfkbia) we show that ifn-α is retained in the cytosol of virus-infected cells and is not secreted. our findings suggest that activated iκbα mediates the export of ifn-α from virus-infected cells and that the inability of cells in mmp12(-/-) but not wild-type mice to express iκbα and thus export ifn-α makes coxsackievirus type b3 infection lethal and renders res ... | 2014 | 24784232 |
| noblesse oblige: nrf2 functions in the airways. | the transcription factor, nuclear factor (nf), erythroid-derived 2-related factor 2 (nrf2), was discovered nearly 2 decades ago. since then, over 4,000 papers have been published on nrf2 function in diverse biological systems, and it has been found to be a critical regulator of antioxidant and defense genes with antioxidant response elements in their promoters. nrf2 is particularly important in protecting cells and tissues under highly oxidative microenvironments, including the airways that inte ... | 2014 | 24783956 |
| prevention and prophylaxis of respiratory syncytial virus in pediatric cardiology: a uk perspective. | respiratory syncytial virus (rsv) is a common infection, causing bronchiolitis in over 70% of infants each year and almost all children by the age of 2. it is the leading cause of acute lower respiratory tract infections and admissions to hospital worldwide. previously healthy infants may have a prolonged cough or wheezing following rsv infection but up to 20% of those with congenital cardiac disease will be hospitalized and have significant morbidity and mortality. for this reason, it is genera ... | 2014 | 24762251 |
| systematic review and meta-analysis of respiratory syncytial virus infection epidemiology in latin america. | respiratory syncytial virus (rsv) is a frequent cause of acute respiratory infection and the most common cause of bronchiolitis in infants. the aim of this systematic review and meta-analysis was to obtain a comprehensive epidemiological picture of the data available on disease burden, surveillance, and use of resources in latin america. pooled estimates are useful for cross-country comparisons. data from published studies reporting patients with probable or confirmed rsv infection in medical da ... | 2014 | 24757727 |
| palivizumab compliance by infants in puerto rico during the 2009-2010 respiratory syncytial virus season. | respiratory syncytial virus (rsv) is the leading viral pathogen responsible for bronchiolitis and pneumonia in infants. we assessed palivizumab prophylaxis compliance for infants in puerto rico. we retrospectively studied data from 868 infants (409 females, 459 males) during the 2009-2010 rsv season. the infants had a mean gestational age of 33 weeks (range 23-41) and a mean birth weight of 1,767 g (range 509-4,120). only 74 % of the infants with indications received prophylaxis. the main reason ... | 2014 | 24756837 |
| antiviral activity of ginseng extract against respiratory syncytial virus infection. | panax ginseng has been known to have a number of immuno-modulatory effects. in this study, we investigated whether panax korean red ginseng extract (krge) has in vitro and in vivo antiviral effects on respiratory syncytial virus (rsv) infection. krge improved the survival of human lung epithelial cells against rsv infection and inhibited rsv replication. in addition, krge treatment suppressed the expression of rsv-induced inflammatory cytokine genes (il-6 and il-8) and the formation of reactive ... | 2014 | 24756136 |
| development of safe and effective rsv vaccine by modified cd4 epitope in g protein core fragment (gcf). | respiratory syncytial virus (rsv) is a major cause of respiratory tract infection in infants and young children worldwide, but currently no safe and effective vaccine is available. the rsv g glycoprotein (rsvg), a major attachment protein, is an important target for the induction of protective immune responses during rsv infection. however, it has been thought that a cd4+ t cell epitope (a.a. 183-195) within rsvg is associated with pathogenic pulmonary eosinophilia. to develop safe and effective ... | 2014 | 24736750 |
| profiling the approach to the investigation of viral infections in cases of sudden unexpected death in infancy in the western cape province, south africa. | sudden unexpected death in infancy is one of the main contributory factors to high infant mortality rates world-wide. several risk factors, including viral infection, have been implicated in sudi cases, but no single factor has been confirmed as the main cause of death. at the tygerberg medico-legal laboratory, cape town, south africa, investigation of lung tissue for viral infection forms part of an institutional protocol for the examination of cases of sudden unexpected death in infancy. | 2014 | 24727219 |
| respiratory syncytial virus increases lung cellular bioenergetics in neonatal c57bl/6 mice. | we have previously reported that lung cellular bioenergetics (cellular respiration and atp) increased in 4-10 week-old balb/c mice infected with respiratory syncytial virus (rsv). this study examined the kinetics and changes in cellular bioenergetics in ≤ 2-week-old c57bl/6 mice following rsv infection. mice (5-14 days old) were inoculated intranasally with rsv and the lungs were examined on days 1-10 post-infection. histopathology and electron microscopy revealed preserved pneumocyte architectu ... | 2014 | 24725953 |
| escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein. | the role of binding kinetics in determining neutralizing potency for antiviral antibodies is poorly understood. while it is believed that increased steady-state affinity correlates positively with increased virus-neutralizing activity, the relationship between association or dissociation rate and neutralization potency is unclear. we investigated the effect of naturally-occurring antibody resistance mutations in the rsv f protein on the kinetics of binding to palivizumab. escape from palivizumab ... | 2014 | 24725940 |
| a population-based study of childhood respiratory morbidity after severe lower respiratory tract infections in early childhood. | to estimate the risk of childhood chronic respiratory morbidity among those hospitalized for severe lower respiratory tract infection (lrti) in early childhood, and to determine whether severe lrti is an independent predictor. | 2014 | 24725580 |
| evaluating national guidelines for the prophylactic treatment of respiratory syncytial virus in children with congenital heart disease. | this is the first study to evaluate compliance with the 2003 swedish national guidelines for prophylactic treatment of respiratory syncytial virus (rsv) in children with congenital heart disease (chd). we estimated the relative risk (rr) of children with chd being hospitalised with a rsv infection, studied the extent to which rsv prophylactic treatment with palivizumab corresponded to the guidelines and determined the morbidity of children with chd who developed rsv infection despite prophylaxis ... | 2014 | 24724913 |
| rsv-encoded ns2 promotes epithelial cell shedding and distal airway obstruction. | respiratory syncytial virus (rsv) infection is the major cause of bronchiolitis in young children. the factors that contribute to the increased propensity of rsv-induced distal airway disease compared with other commonly encountered respiratory viruses remain unclear. here, we identified the rsv-encoded nonstructural 2 (ns2) protein as a viral genetic determinant for initiating rsv-induced distal airway obstruction. infection of human cartilaginous airway epithelium (hae) and a hamster model of ... | 2014 | 24713657 |
| palivizumab and respiratory syncytial virus disease: selling sickness for future? | over the past two decades russia has gone through dramatic "democratic" changes resulting in unprecedented deterioration of health, loss of lives and extinction of population. the health system turned into a ridiculous monster of poorly organized business exploiting reminiscent social values of the past to build profits on selling sickness-for-all in consumer culture. we present facts and conclude that introduction of palivizumab into clinical practice for the most vulnerable patient category wa ... | 2014 | 24796349 |
| mucosal vaccines against respiratory syncytial virus. | respiratory syncytial virus (rsv) is a leading cause of severe respiratory disease in infants, young children, immune-compromised and elderly populations worldwide. natural rsv infection in young children does not elicit long-lasting immunity and individuals remain susceptible to repeated rsv infections throughout life. because rsv infection is restricted to the respiratory tract, an rsv vaccine should elicit mucosal immunity at upper and lower respiratory tracts in order to most effectively pre ... | 2014 | 24794644 |
| exposure to infections and risk of leukemia in young children. | epidemiologic studies indicate that infections in early childhood may protect against pediatric acute lymphoblastic leukemia (all). | 2014 | 24793957 |
| micrornas and the immune response to respiratory virus infections. | micrornas (mirnas) are small ssrna molecules, which are involved in gene expression regulation at the post-transcriptional level. their biological functions include modulation of both innate and adaptive immune response. mirnas participate in the maintenance of the airway epithelial barrier and are also implicated in the modulation of antiviral defense in epithelial cells. the immune response to respiratory viruses such as rhinovirus, influenza virus and respiratory syncytial virus is associated ... | 2014 | 24784476 |
| dngr-1 is dispensable for cd8+ t-cell priming during respiratory syncytial virus infection. | during respiratory syncytial virus (rsv) infection cd8(+) t cells both assist in viral clearance and contribute to immunopathology. cd8(+) t cells recognize viral peptides presented by dendritic cells (dcs), which can directly present viral antigens when infected or, alternatively, "cross-present" antigens after endocytosis of dead or dying infected cells. mouse cd8α(+) and cd103(+) dcs excel at cross-presentation, in part because they express the receptor dngr-1 that detects dead cells by bindi ... | 2014 | 24777856 |
| characterization of a respiratory syncytial virus l protein inhibitor. | the respiratory syncytial virus (rsv) l protein is a viral rna-dependent rna polymerase that contains multiple enzyme activities required for rsv replication. the rsv l inhibitors described in literature are limited by their cytotoxicity or the lack of rsv b subtype coverage. here, we characterize a new rsv l inhibitor with strong antiviral activity against both rsv a and b subtypes and no detectable cytotoxicity. this compound, az-27, was equally active against rsv live viruses and subgenomic r ... | 2014 | 24777090 |
| adults face increased asthma risk after infant rsv bronchiolitis and reduced respiratory health-related quality of life after rsv pneumonia. | to evaluate the association between hospitalisation for respiratory syncytial virus lower respiratory tract infection (rsv lrti) in infancy and asthma, respiratory health-related quality of life and lung function at 28-31 years of age. | 2014 | 24766320 |
| an overview of respiratory syncytial virus. | 2014 | 24763387 | |
| distinct regulation of tonsillar immune response in virus infection. | the relationships between tonsillar immune responses, and viral infection and allergy are incompletely known. | 2014 | 24684577 |
| depletion of circulating regulatory t cells during severe respiratory syncytial virus infection in young children. | 2014 | 24684360 | |
| glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. | respiratory syncytial virus (rsv) can cause devastating lower respiratory tract infections in preterm infants or when other serious health problems are present. immunoprophylaxis with palivizumab (synagis), a humanized igg1 mab, is the current standard of care for preventing rsv infection in at-risk neonates. we have explored the contribution of effector function to palivizumab efficacy using a plant-based expression system to produce palivizumab n-glycan structure variants with high homogeneity ... | 2014 | 24711420 |
| prevention and treatment of viral respiratory infections by traditional chinese herbs. | this review focuses on current knowledge of traditional chinese herbs on prevention and treatment of viral respiratory infections, especially caused by severe acute respiratory syndromes (sars) virus, respiratory syncytial virus (rsv) and influenza viruses. | 2014 | 24709192 |
| clinical efficacy of montelukast sodium in treating infantile wheezing. | the efficacy and safety of a single-dose of montelukast sodium for treating virus-related infantile wheezing are investigated in this study. | 2014 | 24706299 |
| bushenyiqi formula strengthens th1 response and suppresses th2-th17 responses in rsv-induced asthma exacerbated mice. | the prevalence of allergic asthma has been increased rapidly in recent years. about 20% of all these sufferers have experienced asthma exacerbation. although corticosteroids and β-agonists therapy improves serious asthma symptoms, they can׳t completely cure these allergic diseases. bushenyiqi formula (bsyqf) has been widely used to treat bronchial asthma and its exacerbation for decades in huashan hospital of fudan university, china. nevertheless, the mechanisms of bsyqf' anti-asthmatic effects ... | 2014 | 24704667 |
| infectious pathogens and bronchiolitis outcomes. | bronchiolitis is a common early childhood illness and an important cause of morbidity, it is the number one cause of hospitalization among us infants. bronchiolitis is also an active area of research, and recent studies have advanced our understanding of this illness. although it has long been the conventional wisdom that the infectious etiology of bronchiolitis does not affect outcomes, a growing number of studies have linked specific pathogens of bronchiolitis (e.g., rhinovirus) to short- and ... | 2014 | 24702592 |
| immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with rsv infections. | we developed an immunodeficiency scoring index for respiratory syncytial virus (isi-rsv) infection, based on a cohort of 237 allogeneic hematopoietic cell transplant (allo-hct) recipients, that can predict the risk of progression to lower respiratory tract infection (lrti) and rsv-associated mortality. a weighted index was calculated using adjusted hazard ratios for immunodeficiency markers. based on the isi-rsv (range, 0-12), patients were stratified into low (0-2), moderate (3-6), and high (7- ... | 2014 | 24700783 |
| [differentiation of influenza (flu) type a, type b, and respiratory syncytial virus (rsv) by quicknavi™-flu+rsv]. | because it is not easy to differentiate influenza virus (flu) from rs virus (rsv) just by clinical symptoms, to accurately diagnose those viruses in conjunction with patient's clinical symptoms, rapid diagnostic kits has been used separately for each of those viruses. in our new study, we have developed a new rapid diagnostic kit, quicknavi™-flu+rsv. the kit can detect flu a, flu b, and rsv antigens with a single sample collection and an assay. total of 2,873 cases (including nasopharyngeal swab ... | 2014 | 24694242 |
| authors' response re: clarifying costs and benefits of respiratory syncytial virus immunoprophylaxis. | 2014 | 24692038 | |
| clarifying costs and benefits of respiratory syncytial virus immunoprophylaxis. | 2014 | 24692037 | |
| examining strain diversity and phylogeography in relation to an unusual epidemic pattern of respiratory syncytial virus (rsv) in a long-term refugee camp in kenya. | a recent longitudinal study in the dadaab refugee camp near the kenya-somalia border identified unusual biannual respiratory syncytial virus (rsv) epidemics. we characterized the genetic variability of the associated rsv strains to determine if viral diversity contributed to this unusual epidemic pattern. | 2014 | 24690157 |
| respiratory syncytial virus disease in preterm infants in the u.s. born at 32-35 weeks gestation not receiving immunoprophylaxis. | the respiratory syncytial virus (rsv) respiratory events among preterm infants outcomes and risk tracking (report) study evaluated rsv disease burden in u.s. preterm infants 32-35 weeks gestational age (wga) not receiving rsv prophylaxis. | 2014 | 24622396 |
| oral ribavirin therapy for respiratory syncytial virus infections in moderately to severely immunocompromised patients. | respiratory syncytial virus (rsv) infections may be fatal in immunocompromised patients. aerosolized ribavirin is used for treatment, but it is very costly, teratogenic, and inconvenient. we aimed to assess the outcome of oral ribavirin treatment, with or without intravenous immunoglobulin (ivig), for rsv infections in moderately to severely immunocompromised patients. | 2014 | 24621016 |
| real-time light scattering tracking of gold nanoparticles- bioconjugated respiratory syncytial virus infecting hep-2 cells. | real-time tracking of virus invasion is crucial for understanding viral infection mechanism, which, however, needs simple and efficient labeling chemistry with improved signal-to-noise ratio. for that purpose, herein we investigated the invasion dynamics of respiratory syncytial virus (rsv) through dark-field microscopic imaging (idfm) technique by using au nanoparticles (aunps) as light scattering labels. rsv, a ubiquitous, non-segmented, pleiomorphic and negative-sense rna virus, is an importa ... | 2014 | 24681709 |
| comparison of urinary tract infection rates among 2- to 12-month-old febrile infants with rsv infections using 1999 and 2011 aap diagnostic criteria. | infants with rsv infections have been found to have a clinically significant rate of urinary tract infections (utis). the american academy of pediatrics (aap) published a revised clinical practice guideline on utis in 2011, which includes major changes in diagnostic criteria for utis. past research has been done using previous diagnostic criteria. the objective of the study is to assess the rate of utis in febrile infants with respiratory syncytial virus (rsv) infections according to the 2011 re ... | 2014 | 24681546 |
| when to perform urine cultures in respiratory syncytial virus-positive febrile older infants? | respiratory syncytial virus (rsv) infections are associated with clinically significant rate of urinary tract infections (utis) in young infants. previous research investigating rsv infections and utis has been performed mainly in infants younger than 2 to 3 months and has not focused on the risk of uti in infants 3 to 12 months. | 2014 | 25162692 |
| randomized, double-blind study of the safety of the liquid versus lyophilized formulation of palivizumab in premature infants and children with chronic lung disease of prematurity. | to avoid the need for reconstitution required by lyophilized palivizumab, a liquid formulation was developed. this study assessed the safety and antidrug antibodies (ada) of the liquid formulation of palivizumab compared with the lyophilized formulation. | 2014 | 25156956 |
| comparison of the simplexa™ flu a/b & rsv kit (nucleic acid extraction-dependent assay) and the prodessa proflu+™ assay for detecting influenza and respiratory syncytial viruses. | the relative performance of 2 widely used reverse transcription polymerase chain reaction (rt-pcr) assays, the focus diagnostics simplexa™ flu a/b & rsv kit (nucleic acid extraction-dependent assay) and the prodessa proflu+™ assay, was evaluated using 735 prospectively and retrospectively collected nasopharyngeal swab specimens. overall, the assays showed positive and negative agreements of 100% and 99.7% for influenza a, 98.1% and 99.9% for influenza b, and 99.3% and 99.5% for respiratory syncy ... | 2014 | 25209363 |
| maternal immunization with chimpanzee adenovirus expressing rsv fusion protein protects against neonatal rsv pulmonary infection. | respiratory syncytial virus (rsv) is a leading cause of lower respiratory tract disease with high morbidity and mortality in young infants and children. despite numerous efforts, a licensed vaccine against rsv remains elusive. since young infants form the primary target group of rsv disease, maternal immunization to boost the protection in neonates is an attractive strategy. in this study we tested the efficacy of maternal immunization with a chimpanzee adenovirus expressing codon-optimized rsv ... | 2014 | 25171847 |
| cross-resistance mechanism of respiratory syncytial virus against structurally diverse entry inhibitors. | respiratory syncytial virus (rsv) is a leading pediatric pathogen that is responsible for a majority of infant hospitalizations due to viral disease. despite its clinical importance, no vaccine prophylaxis against rsv disease or effective antiviral therapeutic is available. in this study, we established a robust high-throughput drug screening protocol by using a recombinant rsv reporter virus to expand the pool of rsv inhibitor candidates. mechanistic characterization revealed that a potent newl ... | 2014 | 25092342 |
| ribavirin: the need for exposure precautions. | ribavirin is used in the treatment of respiratory syncytial virus (rsv) in high-risk patients, including patients who have undergone hematopoietic stem cell transplantation, to reduce mortality from rsv pneumonia. it is classified as a hazardous drug with potential for carcinogenicity and teratogenicity. very few recent studies have examined the risk of exposure, and recommendations for exposure precautions are lacking. administration should include the use of personal protective equipment and t ... | 2014 | 25253120 |
| common questions about outpatient care of premature infants. | preterm births (deliveries before 37 weeks' gestation) comprise 12% of all u.s. births and are responsible for onethird of all infant deaths. neonatal medical advances have increased survival, and primary care physicians often care for infants who were in the neonatal intensive care unit after birth. functions of the primary care physician include coordination of medical and social services, nutritional surveillance, and managing conditions associated with prematurity. parental guidance and enco ... | 2014 | 25250998 |
| refining the balance of attenuation and immunogenicity of respiratory syncytial virus by targeted codon deoptimization of virulence genes. | respiratory syncytial virus (rsv) is the most important pathogen for lower respiratory tract illness in children for which there is no licensed vaccine. live-attenuated rsv vaccines are the most clinically advanced in children, but achieving an optimal balance of attenuation and immunogenicity is challenging. one way to potentially retain or enhance immunogenicity of attenuated virus is to mutate virulence genes that suppress host immune responses. the ns1 and ns2 virulence genes of the rsv a2 s ... | 2014 | 25249281 |
| seroprevalence of respiratory syncytial virus igg among healthy young adults in basic training for the republic of korea air force. | this investigation enrolled 570 healthy young males gathered from all over the country for military service at the republic of korea air force boot camp. it confirmed rsv igg seroprevalence by utilizing the enzyme immunoassay method just prior to undergoing basic training. the mean age of this study was 20.25 ± 1.34 yr old. the results of their immunoassay seroprofiles showed that 561 men (98.4%) were positive, 2 (0.4%) were negative and 7 (1.2%) were equivocal belonging to the grey zone. it was ... | 2014 | 25246755 |
| additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins. | respiratory syncytial virus (rsv) is the most important pathogen for lower respiratory tract illness in infants and a high priority for vaccine development. we previously reported that rsv virus-like particles (vlps) expressing either the fusion (f) or attachment (g) glycoprotein could confer protection against rsv challenge in balb/c mice. here, we tested the hypothesis that rsv vlp vaccine efficacy can be enhanced by mixing rsv vlp f and rsv vlp g, and we analyzed host responses to these rsv v ... | 2014 | 25239522 |
| epidemiologic differences of four major respiratory viruses between children, adolescents, and adults in korea. | the purpose of this study was to investigate the epidemiology of four major respiratory viruses among the korean population. this retrospective study was conducted over four years, from january 2005 to december 2008. among a total of 23,806 specimens, 5512 virus isolates underwent culture for influenza a and b viruses (ifa/b), parainfluenza virus (piv), respiratory syncytial virus (rsv), and adenovirus (adv). patients were divided into two groups: children/adolescents and adults. the viruses det ... | 2014 | 25179390 |
| nosocomial respiratory syncytial virus infections in the palivizumab-prophylaxis era with implications regarding high-risk infants. | although respiratory syncytial virus (rsv) infection continues to be a leading cause of infant hospitalization with a high transmission rate, recent data on nosocomial rsv infection are scarce. this study investigated the clinical and epidemiologic characteristics of nosocomial rsv infection in the palivizumab-prophylaxis era. | 2014 | 25179332 |
| baculovirus-expressed virus-like particle vaccine in combination with dna encoding the fusion protein confers protection against respiratory syncytial virus. | respiratory syncytial virus (rsv) is a major viral agent causing significant morbidity and mortality in young infants and the elderly. there is no licensed vaccine against rsv and it is a high priority to develop a safe rsv vaccine. we determined the immunogenicity and protective efficacy of combined virus-like particle and dna vaccines presenting rsv glycoproteins (fd.vlp) in comparison with formalin inactivated rsv (fi-rsv). immunization of mice with fd.vlp induced higher ratios of igg2a/igg1 ... | 2014 | 25173478 |
| double-stapled respiratory syncytial virus may prevent nasopulmonary infection. | 2014 | 25226620 | |
| the use of a multiplex real-time pcr assay for diagnosing acute respiratory viral infections in children attending an emergency unit. | the use of a multiplex molecular technique to identify the etiological pathogen of respiratory viral infections might be a support as clinical signs are not characteristic. | 2014 | 25223920 |
| hospital length-of-stay is associated with rhinovirus etiology of bronchiolitis. | to determine whether hospital length-of-stay (los) for bronchiolitis is influenced by the causative virus: respiratory syncytial virus (rsv) or rhinovirus. | 2014 | 25222302 |
| diagnosing heart failure in children with congenital heart disease and respiratory syncytial virus bronchiolitis. | the objective of this study is to examine if the b-type natriuretic peptide (bnp) can be used in diagnosing heart failure (hf) in children with congenital heart disease (chd) who present to the emergency department (ed) with acute bronchiolitis. | 2014 | 25261398 |
| challenges and future in vaccines, drug development, and immunomodulatory therapy. | pulmonary diseases and infections are among the top contributors to human morbidity and mortality worldwide, and despite the successful history of vaccines and antimicrobial therapeutics, infectious disease still presents a significant threat to human health. effective vaccines are frequently unavailable in developing countries, and successful vaccines have yet to be developed for major global maladies, such as tuberculosis. furthermore, antibiotic resistance poses a growing threat to human heal ... | 2014 | 25148426 |
| oral gs-5806 activity in a respiratory syncytial virus challenge study. | respiratory syncytial virus (rsv) is a common cause of infant hospitalizations and is increasingly recognized as a cause of considerable morbidity and mortality. no accepted antiviral treatment exists. | 2014 | 25140957 |
| 'they said it was bronchiolitis; is it going to turn into asthma doctor?'. | acute bronchiolitis is a common paediatric disease of infancy. its association with subsequent asthma development has puzzled clinicians and epidemiologists for decades. this article reviews the current state of knowledge regarding the role of acute bronchiolitis in the inception of asthma. there is little doubt that acute bronchiolitis is associated with an increased risk of recurrent wheezing throughout the primary school years although the direction of causality--i.e. whether bronchiolitis in ... | 2014 | 25138566 |
| the burden of influenza and rsv among inpatients and outpatients in rural western kenya, 2009-2012. | in kenya, detailed data on the age-specific burden of influenza and rsv are essential to inform use of limited vaccination and treatment resources. | 2014 | 25133576 |
| respiratory syncytial virus infection in high-risk infants - an update on palivizumab prophylaxis. | morbidity due to respiratory syncytial virus (rsv) disease is still high in infants and children worldwide during the first two to five years of life. certain categories of high-risk infants with increased morbidity and mortality attributed to rsv disease have been identified and are included in national recommendations for prophylaxis with the monoclonal rsv antibody palivizumab. most guidelines recommend palivizumab for preterm infants born less than or equal to 32 weeks gestational age with o ... | 2014 | 25132870 |
| lactate dehydrogenase and caspase activity in nasopharyngeal secretions are predictors of bronchiolitis severity. | bronchiolitis is the leading cause of hospitalization in infants. biomarkers of disease severity might help in clinical management. | 2014 | 25132512 |
| alleviation of respiratory syncytial virus replication and inflammation by fungal immunomodulatory protein fip-fve from flammulina velutipes. | respiratory syncytial virus (rsv) causes bronchiolitis in children followed by inflammation and asthma-like symptoms. the development of preventive therapy for this virus continues to pose a challenge. fungal immunomodulatory proteins (fips) exhibit anti-inflammatory function. fip-fve is an immunomodulatory protein isolated from flammulina velutipes. to determine whether fip-fve affects the infection or consequence of immunity of rsv, we investigated viral titers of rsv and inflammatory cytokine ... | 2014 | 25131377 |
| a colorimetric immunoassay for respiratory syncytial virus detection based on gold nanoparticles-graphene oxide hybrids with mercury-enhanced peroxidase-like activity. | a novel colorimetric immunoassay for highly sensitive detection of respiratory syncytial virus (rsv), one of the leading causes of severe lower respiratory tract infections in all age groups, has been proposed based on hg(2+)-stimulated peroxidase-like activity of gold nanoparticles-graphene oxide (aunps-go) hybrids. this metal ion-enhanced immunoassay shows high promise in the field of biomedical sciences. | 2014 | 25131342 |
| ifn-γ ca microsatellite polymorphism is associated with susceptibility to respiratory syncytial virus infection and severity. | ifn-γ, an essential cytokine in the viral cell-mediated immune response, has been associated with the pathogenesis of respiratory syncytial virus (rsv) bronchiolitis and to the severity of the infection. the aim of this study was to investigate whether ifn-γ ca microsatellite (rs3138557) polymorphism was associated with susceptibility to rsv in chinese han children and with the severity of the infection. | 2014 | 25130433 |
| [modelling respiratory syncytial virus (rsv) transmission children aged less than five years-old]. | studying respiratory syncytial virus (rsv) transmission dynamics in a population of children aged less than 5 years-old using deterministic models. | 2014 | 25124134 |
| respiratory syncytial virus infections in infants affected by primary immunodeficiency. | primary immunodeficiencies are rare inherited disorders that may lead to frequent and often severe acute respiratory infections. respiratory syncytial virus (rsv) is one of the most frequent pathogens during early infancy and the infection is more severe in immunocompromised infants than in healthy infants, as a result of impaired t- and b-cell immune response unable to efficaciously neutralize viral replication, with subsequent increased viral shedding and potentially lethal lower respiratory t ... | 2014 | 25089282 |
| ageing and respiratory infections: the airway of ageing. | respiratory infections are a leading cause of infectious disease burden worldwide especially among the elderly. furthermore, a direct relationship between ageing and susceptibility to infections has been reported, which may be caused by impaired immune function, frailty and degree of exposure to infectious diseases. many complex changes, including structural and age-associated decline in immunity are associated with increased pulmonary diseases worldwide and result in a high age-related disease ... | 2014 | 24973652 |
| a novel six consecutive monthly doses of palivizumab prophylaxis protocol for the prevention of respiratory syncytial virus infection in high-risk preterm infants in taiwan. | respiratory syncytial virus (rsv) circulates year round in taiwan. a novel six consecutive monthly doses of palivizumab for rsv prevention protocol has been approved for high risk preterm infants since december 2010. this study aimed to determine the clinical effectiveness and safety of this novel protocol for the prevention of rsv infection. | 2014 | 24971565 |
| [risk factors for acute respiratory syncytial virus infection of lower respiratory tract in hospitalized infants]. | to investigate the clinical epidemiologic characteristics and analyze risk factors for acute respiratory syncytial virus (rsv) infection in hospitalized infants with acute lower respiratory tract infection (alri). | 2014 | 24969937 |
| a bayesian sirs model for the analysis of respiratory syncytial virus in the region of valencia, spain. | we present a bayesian stochastic susceptible-infected-recovered-susceptible (sirs) model in discrete time to understand respiratory syncytial virus dynamics in the region of valencia, spain. a sirs model based on ordinary differential equations has also been proposed to describe rsv dynamics in the region of valencia. however, this continuous-time deterministic model is not suitable when the initial number of infected individuals is small. stochastic epidemic models based on a probability of dis ... | 2014 | 25088210 |
| a monomeric uncleaved respiratory syncytial virus f antigen retains prefusion-specific neutralizing epitopes. | respiratory syncytial virus (rsv) is the leading infectious cause of severe respiratory disease in infants and a major cause of respiratory illness in the elderly. there remains an unmet vaccine need despite decades of research. insufficient potency, homogeneity, and stability of previous rsv fusion protein (f) subunit vaccine candidates have hampered vaccine development. rsv f and related parainfluenza virus (piv) f proteins are cleaved by furin during intracellular maturation, producing disulf ... | 2014 | 25078705 |
| demonstrating the use of high-volume electronic medical claims data to monitor local and regional influenza activity in the us. | fine-grained influenza surveillance data are lacking in the us, hampering our ability to monitor disease spread at a local scale. here we evaluate the performances of high-volume electronic medical claims data to assess local and regional influenza activity. | 2014 | 25072598 |
| updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. | palivizumab was licensed in june 1998 by the food and drug administration for the reduction of serious lower respiratory tract infection caused by respiratory syncytial virus (rsv) in children at increased risk of severe disease. since that time, the american academy of pediatrics has updated its guidance for the use of palivizumab 4 times as additional data became available to provide a better understanding of infants and young children at greatest risk of hospitalization attributable to rsv in ... | 2014 | 25070315 |
| updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. | guidance from the american academy of pediatrics (aap) for the use of palivizumab prophylaxis against respiratory syncytial virus (rsv) was first published in a policy statement in 1998. guidance initially was based on the result from a single randomized, placebo-controlled clinical trial conducted in 1996-1997 describing an overall reduction in rsv hospitalization rate from 10.6% among placebo recipients to 4.8% among children who received prophylaxis. the results of a second randomized, placeb ... | 2014 | 25070304 |
| screening for respiratory syncytial virus and isolation strategies in children hospitalized with acute respiratory tract infection. | nosocomial infection with respiratory syncytial virus (rsv) is an important health risk in pediatric care but is largely preventable by efficient infection control measures. commonly applied rapid antigen detection tests (radts) miss a considerable number of rsv-infected patients. the objective of our analysis was to evaluate whether readily available host parameters are associated with false-negative radt, and to assess how these parameters could be applied in an optimized rsv isolation strateg ... | 2014 | 25437026 |
| il-6 receptor α defines effector memory cd8+ t cells producing th2 cytokines and expanding in asthma. | cytokine receptors can be markers defining different t-cell subsets and considered as therapeutic targets. the association of il-6 and il-6 receptor α (il-6rα) with asthma was reported, suggesting their involvement in asthma. | 2014 | 25390970 |
| [vrs bronchiolitis with severe hyponatremia leading to acute seizures: a report of three cases]. | acute bronchiolitis due to respiratory syncytial virus (rsv) can present with extrapulmonary manifestations, notably severe hyponatremia. hyponatremia is caused by excess secretion of antidiuretic hormone and can be exacerbated by intravenous infusion of hypotonic solutions. we report three cases of infants admitted for acute bronchiolitis and hyponatremia leading to acute seizures. we describe how hyponatremia was corrected and analyze the management aspects that might have worsened the magnitu ... | 2014 | 25445128 |
| the first wheezing episode: respiratory virus etiology, atopic characteristics, and illness severity. | susceptibility to early rhinovirus-induced wheezing has been recognized as an important risk factor for childhood asthma, but data on the first wheezing episode are limited. the aim of this selected population study was to investigate virus etiology, atopic characteristics, and illness severity, as well as their interrelation, among first-time wheezing children. | 2014 | 25444257 |
| optimization of potent and selective quinazolinediones: inhibitors of respiratory syncytial virus that block rna-dependent rna-polymerase complex activity. | a quinazolinedione-derived screening hit 2 was discovered with cellular antiviral activity against respiratory syncytial virus (cpe ec50 = 2.1 μm), moderate efficacy in reducing viral progeny (4.2 log at 10 μm), and marginal cytotoxic liability (selectivity index, si ∼ 24). scaffold optimization delivered analogs with improved potency and selectivity profiles. most notable were compounds 15 and 19 (ec50 = 300-500 nm, cc50 > 50 μm, si > 100), which significantly reduced viral titer (>400,000-fold ... | 2014 | 25399509 |
| inhibitors of the interferon response enhance virus replication in vitro. | virus replication efficiency is influenced by two conflicting factors, kinetics of the cellular interferon (ifn) response and induction of an antiviral state versus speed of virus replication and virus-induced inhibition of the ifn response. disablement of a virus's capacity to circumvent the ifn response enables both basic research and various practical applications. however, such ifn-sensitive viruses can be difficult to grow to high-titer in cells that produce and respond to ifn. the current ... | 2014 | 25390891 |
| utilization of viral molecular diagnostics among children hospitalized with community acquired pneumonia. | to examine whether results of a polymerase chain reaction-based respiratory viral panel (rvp) are associated with changes in antibiotic use or differential clinical outcomes among children hospitalized with pneumonia. | 2014 | 25362079 |
| the burden of single virus and viral coinfections on severe lower respiratory tract infections among preterm infants: a prospective birth cohort study in brazil. | respiratory syncytial virus (rsv) is associated with severe lower respiratory tract infection (lrti), especially in preterm infants. other viruses, co-detected with rsv, may play a role in the severity of respiratory outcomes. | 2014 | 25361184 |
| clinical risk factors for life-threatening lower respiratory tract infections in children: a retrospective study in an urban city in malaysia. | lower respiratory tract infections (lrtis) are an important cause of morbidity and mortality, especially in low income countries. the aim of this study was to determine risk factors of life-threatening lrtis in hospitalised children in malaysia. | 2014 | 25360811 |
| viral etiology of respiratory tract infections in children at the pediatric hospital in ouagadougou (burkina faso). | acute respiratory infections (aris) are a major cause of morbidity and mortality in children in africa. the circulation of viruses classically implicated in aris is poorly known in burkina faso. the aim of this study was to identify the respiratory viruses present in children admitted to or consulting at the pediatric hospital in ouagadougou. | 2014 | 25360527 |
| prolonged seasonality of respiratory syncytial virus infection among preterm infants in a subtropical climate. | there is limited epidemiological data on the seasonality of respiratory syncytial virus (rsv) infection in subtropical climates, such as in taiwan. this study aimed to assess rsv seasonality among children ≤24 months of age in taiwan. we also assessed factors (gestational age [ga], chronologic age [ca], and bronchopulmonary dysplasia [bpd]) associated with rsv-associated hospitalization in preterm infants to confirm the appropriateness of the novel taiwanese rsv prophylactic policy. | 2014 | 25333346 |
| social, economic, and health impact of the respiratory syncytial virus: a systematic search. | bronchiolitis caused by the respiratory syncytial virus (rsv) and its related complications are common in infants born prematurely, with severe congenital heart disease, or bronchopulmonary dysplasia, as well as in immunosuppressed infants. there is a rich literature on the different aspects of rsv infection with a focus, for the most part, on specific risk populations. however, there is a need for a systematic global analysis of the impact of rsv infection in terms of use of resources and healt ... | 2014 | 25358423 |
| [respiratory virus infections in adult patients hospitalized in an internal medicine unit]. | respiratory viral infections (rvi) can be associated with a wide range of clinical manifestations. | 2014 | 25327313 |
| management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies. | despite preventive strategies and increased awareness, a high incidence of respiratory viral infections still occur in patients with hematologic malignancies (hms) and in recipients of hematopoietic cell transplant (hct). progression of these viral infections to lower respiratory tract may prove fatal, especially in hct recipients. increasing evidence on the successful use of ribavirin (alone or in combination with immunomodulators) for the treatment of respiratory syncytial virus infections in ... | 2014 | 25352629 |
| clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. | this guideline is a revision of the clinical practice guideline, "diagnosis and management of bronchiolitis," published by the american academy of pediatrics in 2006. the guideline applies to children from 1 through 23 months of age. other exclusions are noted. each key action statement indicates level of evidence, benefit-harm relationship, and level of recommendation. key action statements are as follows: | 2014 | 25349312 |
| reprint of: perinatal and early childhood environmental factors influencing allergic asthma immunopathogenesis. | the prevalence of asthma has increased dramatically over the past several decades. while hereditary factors are highly important, the rapid rise outstrips the pace of genomic variation. great emphasis has been placed on potential modifiable early life exposures leading to childhood asthma. | 2014 | 25308874 |
| partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a medicaid population: a retrospective cohort analysis. | infection with respiratory syncytial virus (rsv) is common among young children insured through medicaid in the united states. complete and timely dosing with palivizumab is associated with lower risk of rsv-related hospitalizations, but up to 60% of infants who receive palivizumab in medicaid population do not receive full prophylaxis. the purpose of this study was to evaluate the association of partial palivizumab prophylaxis with the risk of rsv hospitalization among high-risk medicaid-insure ... | 2014 | 25308481 |